tirzepatide effects on liver Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide is a dual incretin

Subsequent Treatment & Monitoring (After Initial Correction) After initial correction, the focus shifts to preventing recurrence, which is a greater concern in diabetic patients due to the ongoing pharmacology of their medications (e.g., long-acting insulin or sulfonylureas)

Muscles rely on glucose for energy, so if there isnt enough, they might not work properly and could cramp up

The findings of the SURMOUNT OSA trial supported this hypothesis, showing a significant improvement in AHI, hypoxic burden and sleep quality with tirzepatide compared to placebo at 52 weeks 38

Mild digestive symptoms are common, particularly when beginning treatment

Cognitive function and sleep in limited observations, a possible link with cognitive indicators, neurometabolic regulation, and sleep quality is considered